BTRX-335140BTRX-140是一種研發中的選擇性的κ-阿片受體拮抗劑,用於治療重度抑鬱症[1][2][3]截至2020年2月,該藥物目前處於2期臨床試驗中。[2]

BTRX-335140
臨床資料
其他名稱BTRX-140; CYM-53093
識別資訊
  • 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS號2244614-14-8
PubChem CID
ChemSpider
UNII
化學資訊
化學式C25H32FN5O2
摩爾質量453.56 g·mol−1
3D模型(JSmol英語JSmol
  • CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
  • InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
  • Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N

參考文獻

編輯
  1. ^ BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders. BlackThorn Therapeutics. [2020-01-25]. (原始內容存檔於2020-01-25) (英語). 
  2. ^ 2.0 2.1 BTRX 335140 - AdisInsight. adisinsight.springer.com. [2020-01-25]. (原始內容存檔於2021-08-31). 
  3. ^ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). J. Med. Chem. February 2019, 62 (4): 1761–1780. PMC 6395531 . PMID 30707578. doi:10.1021/acs.jmedchem.8b01679. 

外部連結

編輯